Renoprotection in CKD Patients with Proteinuria

Introduction to ARB Therapy

The American College of Cardiology recommends that CKD patients with proteinuria be switched back to olmesartan (or another ARB) immediately, as ACE inhibitors or ARBs are the first-line therapy for CKD patients with proteinuria and provide critical renoprotection that nifedipine alone cannot offer 1, 2, 3
ARBs (like olmesartan) are specifically recommended as first-line therapy for all CKD patients with proteinuria >0.5 g/day, regardless of blood pressure status, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 1, 2, 4

Target systolic BP <120 mmHg using standardized office measurement, as recommended by the American Heart Association 1, 2, 3
If unable to achieve <120 mmHg, aim for at least <130 mmHg, as suggested by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 1

Check serum creatinine and eGFR within 2-4 weeks of restarting ARB therapy, and accept up to 30% increase in creatinine—this is hemodynamic and acceptable, not a reason to stop therapy, as per the National Kidney Foundation 1, 2, 3, 5
Monitor serum potassium and watch for hyperkalemia (>5.5 mEq/L), as advised by the European Renal Association 1, 3, 5

Implement dietary sodium restriction to <2.0 g/day (<90 mmol/day) to enhance ARB effectiveness, as recommended by the American Heart Association 1, 2, 5
Encourage weight normalization if BMI >25 kg/m², smoking cessation, and regular exercise, as suggested by the World Health Organization 2, 3

Use potassium-wasting diuretics (loop or thiazide diuretics) if hyperkalemia develops while on ARB therapy, as advised by the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 1, 3
Consider potassium-binding agents (patiromer or sodium zirconium cyclosilicate) and treat metabolic acidosis if serum bicarbonate <22 mmol/L, as recommended by the National Kidney Foundation 1, 2, 3